देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
MESALAZINE
AVIR PHARMA INC.
A07EC02
MESALAZINE
1G
SUPPOSITORY
MESALAZINE 1G
RECTAL
30
Prescription
ANTI-INFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0116808012; AHFS:
APPROVED
2018-03-20
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR MEZERA ® Mesalazine* Suppositories, 1 g / suppository, Rectal Foam, 1 g / actuation (14 actuations per can), Rectal Mfr. Std. *(also known as 5-aminosalicylic acid, 5-ASA or mesalamine) Lower Gastrointestinal Tract Anti-Inflammatory ATC A07EC02 AVIR PHARMA INC. 660 Boul. Industriel Blainville, Quebec J7C 3V4 www.avirpharma.com Date of Initial Authorization: MAR 20, 2018 Date of Revision: DEC 20, 2023 Submission Control Number: 275493 MEZERA® is a registered trade-mark of Dr. Falk Pharma GmbH, used under license by AVIR Pharma Inc. _ _ _MEZERA (mesalazine) _ _Page 2 of 39_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Skin 12/2021 7 WARNINGS AND PRECAUTIONS, General 12/2023 7 WARNINGS AND PRECAUTIONS, Renal 12/2023 7 WARNINGS AND PRECAUTIONS, Sensitivity/Resistance 12/2023 7 WARNINGS AND PRECAUTIONS, Skin 12/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics .............................................................................................................. 4 1.2 Geriatrics .............................................................................................................. 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION ................................................................................. 5 4.1 Dosing Considerations ............................... पूरा दस्तावेज़ पढ़ें